Navigation Links
Stanford and SanBio Announce a Clinical Trial of Cell Therapy for Stroke Disability
Date:4/21/2011

MOUNTAIN VIEW, Calif. and STANFORD, Calif., April 21, 2011 /PRNewswire/ -- The Stanford University School of Medicine and SanBio Inc. today announced the initiation of a Phase 1/2a clinical trial testing the safety and efficacy of a novel allogeneic cell therapy product, SB623, on patients suffering from stable deficits resulting from previous stroke injuries. For details regarding this clinical trial, please refer to the Clinicaltials.gov website http://www.clinicaltrials.gov/ct2/show/NCT01287936.

SB623 is derived from adult bone marrow and has shown safety and efficacy in rodent models of stroke disability.   "SB623 represents a significant step forward in the development of regenerative therapies for the treatment of brain injury," said Keita Mori, SanBio CEO.   "We are pleased to initiate a first-in-man study of SB623."

SB623 will be administered by intracranial injection into the damaged region of the brains of patients who have suffered an ischemic stroke.  Product safety is the primary focus of the study but various measurements of efficacy will also be tested.

"This is a completely new approach to therapy for stroke victims," said Dr. Gary Steinberg, the Lacroute-Hearst Professor, Chairman of the Department of Neurosurgery, and Director of the Stanford Institute for Neuro-Innovation and Translational Neurosciences at the Stanford University School of Medicine, and Principal Investigator of the study.  Sub-Investigator Dr. Neil Schwartz, Clinical Assistant Professor of Neurology, Stanford Stroke Center, said, "If successful, this cell therapy offers hope to otherwise permanently disabled patients."

About SB623: SB623 is a proprietary regenerative cell therapy consisting of cells derived from genetically engineered bone marrow stromal cells obtained from healthy adult donors.  SB623 is implanted directly adjacent to the area damaged by stroke and functions by producing proteins that aid the healing process.

About SanBio: SanBio is a privately held San Francisco Bay Area biotechnology company focused on the discovery and development of new regenerative cell therapy products.

About Stanford: Stanford University Medical Center integrates research, medical education and patient care at its three institutions - Stanford University School of Medicine, Stanford Hospital & Clinics, and Lucile Packard Children's Hospital.  For more information, please visit the Office of Communication & Public Affairs site at http://mednews.stanford.edu/.

For more information: www.san-bio.com


'/>"/>
SOURCE SanBio Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Vermillion and Stanford Scientists Receive Best Research Award From the PAD Coalition
2. Stanford: Quantum computing spins closer
3. Cell Biosciences Delivers Next Generation System to Stanford University
4. Artemis Health Licenses Prenatal Cell-Free DNA Analysis Technology from Stanford University
5. Stanford writes in worlds smallest letters
6. Kornberg Associates Architects Selected to Develop Design for New Stanford University Imaging Center
7. Stanford researchers find a quicker, cheaper way to sort isotopes
8. Eiger BioPharmaceuticals Acquires Exclusive License to Novel Hepatitis C Virus (HCV) Technology From Stanford University
9. LASIK Expert Edward Manche, M.D., of the Stanford Eye Laser Center Joins Top Surgeons Listed at the Trusted LASIK Surgeons Directory
10. New technique reinforces immune cells that seek and destroy cancer, says Stanford researcher
11. Stanford scientists develop new way to grow adult stem cells in culture
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... 11, 2017 , ... Proscia Inc ., a data ... titled, “Pathology is going digital. Is your lab ready?” with Dr. Nicolas Cacciabeve, ... and how Proscia improves lab economics and realizes an increase in diagnostic confidence.* ...
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , ... of Cancer Research, London (ICR) and ... with SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple ... as MUK nine . The University of ... is partly funded by Myeloma UK, and ICR will perform ...
(Date:10/11/2017)... Austin, TX (PRWEB) , ... October 11, 2017 ... ... in August compared the implantation and pregnancy rates in frozen and fresh ... the contribution of progesterone and maternal age to IVF success. , After comparing ...
(Date:10/10/2017)... ... October 10, 2017 , ... San Diego-based team building and cooking ... initiative announced today. The bold new look is part of a transformation to ... into a significant growth period. , It will also expand its service offering from ...
Breaking Biology Technology:
(Date:5/23/2017)... robotic gym for the rehabilitation and functional motor sense evaluation of lower ... . The first 30 robots will be available from June in ... The technology was developed and patented at the IIT laboratories and has ... to a 10 million euro investment from entrepreneur Sergio Dompè. ... ...
(Date:4/19/2017)... 19, 2017 The global military ... is marked by the presence of several large global ... by five major players - 3M Cogent, NEC Corporation, ... for nearly 61% of the global military biometric market ... the global military biometrics market boast global presence, which ...
(Date:4/11/2017)... GARDENS, Fla. , April 11, 2017 /PRNewswire/ ... management and secure authentication solutions, today announced that ... by Intelligence Advanced Research Projects Activity (IARPA) to ... IARPA,s Thor program. "Innovation has been ... and IARPA,s Thor program will allow us to ...
Breaking Biology News(10 mins):